Cancer medicines
Gilteritinib
Gilteritinib
A targeted therapy for selected FLT3-mutated AML.
Sources checked · Introductory guide
On this page
How it works
It inhibits kinase signaling including FLT3 to limit cancer growth.[3]
Where it is used
Used in adults with relapsed or refractory AML and a confirmed FLT3 mutation.[1]
Key safety points
Differentiation syndrome can be severe. Report fever, sudden weight gain, swelling or breathlessness immediately; confirm ECG and electrolyte monitoring.[2]
Questions for your care team
- How are my FLT3 result, differentiation symptoms and cardiac monitoring reviewed?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- NCI · Gilteritinib Fumarate (opens in a new tab)
- MedlinePlus · Gilteritinib Fumarate (opens in a new tab)
- NCI Drug Dictionary · Gilteritinib Fumarate (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.